EOM PHARMACEUTICAL HLDNGS (IMUC) Financials

EOM PHARMACEUTICAL HLDNGS (IMUC) had EBITDA of -$21.1M in fiscal year 2017, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2017, EOM PHARMACEUTICAL HLDNGS (IMUC) had $6.6M in cash and equivalents against $0 in long-term debt.

EOM PHARMACEUTICAL HLDNGS (IMUC) has a return on equity of -307.9% for fiscal year 2017, measuring how efficiently the company generates profit from shareholder equity.

EOM PHARMACEUTICAL HLDNGS (IMUC) recorded an outflow of $16.7M in free cash flow during fiscal year 2017. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

EOM PHARMACEUTICAL HLDNGS (IMUC) recorded an outflow of $16.7M in operating cash flow during fiscal year 2017, representing cash used by core business activities.

EOM PHARMACEUTICAL HLDNGS (IMUC) had $7.0M in total assets as of fiscal year 2017, including both current and long-term assets.

EOM PHARMACEUTICAL HLDNGS (IMUC) reported no capital expenditure during fiscal year 2017.

EOM PHARMACEUTICAL HLDNGS (IMUC) invested $17.1M in research and development during fiscal year 2017.

EOM PHARMACEUTICAL HLDNGS (IMUC) had 42M shares outstanding as of fiscal year 2017.

EOM PHARMACEUTICAL HLDNGS (IMUC) had a current ratio of 2.97 as of fiscal year 2017, which is generally considered healthy.

EOM PHARMACEUTICAL HLDNGS (IMUC) had a debt-to-equity ratio of 0.00 as of fiscal year 2017. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

EOM PHARMACEUTICAL HLDNGS (IMUC) had a liabilities-to-equity ratio of 0.51 as of fiscal year 2017, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

EOM PHARMACEUTICAL HLDNGS (IMUC) had a return on assets of -204.2% for fiscal year 2017, measuring how efficiently the company uses its assets to generate profit.

EOM PHARMACEUTICAL HLDNGS (IMUC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2017). The market capitalization is $9.5M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

EOM PHARMACEUTICAL HLDNGS (IMUC) has no price-to-sales ratio at the moment: revenue is not positive (FY2017). The market capitalization is $9.5M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2017, EOM PHARMACEUTICAL HLDNGS (IMUC) held $6.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

EOM PHARMACEUTICAL HLDNGS (IMUC) has an Altman Z-Score of -30.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

EOM PHARMACEUTICAL HLDNGS (IMUC) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

EOM PHARMACEUTICAL HLDNGS (IMUC) reported a net loss of $14.3M while operations used $16.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

EOM PHARMACEUTICAL HLDNGS (IMUC) reported an operating loss of $21.2M against $883K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.